{"entity":{"id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of ABP1011T in small-cell lung cancer, run by Shanghai AB PharmaTech Ltd., now recruiting.","summary":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07321574 by Shanghai AB PharmaTech Ltd., with 110 participants planned, started 2025-12-30 and due to reach its primary completion in 2028-11-28. Interventions recorded: ABP1011T.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07321574","url":"https://clinicaltrials.gov/study/NCT07321574"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07321574","phase":"2","setting":"An Open-Label, Multi-Cohort Phase IIb Clinical Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","sponsor":"Shanghai AB PharmaTech Ltd.","enrolled":110,"outcomes":[]},"route":"/trials/nct07321574/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}]}}